Akasaka Toshiyuki, Funaki Hiroyoshi, Hirano Shigeru, Ohinata Mitsuru, Fujishima Mikihiko, Kudou Takuji, Suzuki Akira, Iinuma Masahiro
Department of Urology, Akasaka Hospital.
Hinyokika Kiyo. 2003 Apr;49(4):189-93.
Naftopidil was administered to 67 patients with benign prostatic hyperplasia (BPH) for 12 months. Changes in total/each International Prostate Symptom Score (IPSS) for irritative and obstructive symptoms, nocturia, and residual urine volume were compared before and after its administration. As a result, a significant decrease of score was found in total-IPSS, obstructive and irritative symptoms, which also showed a tendency to decrease at the end of the first month. Nocturia and residual urine volume also significantly decreased after its administration. Naftopidil is considered to be effective in the treatment of BPH, especially irritative symptoms including nocturia in treatments for BPH, because both irritative and obstructive symptoms (IPSS subjective endpoints) and residual urine volume (objective endpoint) were improved after its long-term administration.
对67例良性前列腺增生(BPH)患者给予萘哌地尔治疗12个月。比较给药前后刺激性和梗阻性症状、夜尿症及残余尿量的总国际前列腺症状评分(IPSS)/各项IPSS的变化。结果显示,总IPSS、梗阻性和刺激性症状评分显著降低,且在第一个月末也呈下降趋势。给药后夜尿症和残余尿量也显著减少。萘哌地尔被认为对BPH治疗有效,尤其是在BPH治疗中对包括夜尿症在内的刺激性症状有效,因为长期给药后刺激性和梗阻性症状(IPSS主观终点)及残余尿量(客观终点)均得到改善。